Written procedures have not been developed for the surveillance, receipt, evaluation, and reporting to FDA of post marketing adverse drug experiences.
Inspection Record
Jazz Pharmaceuticals, Inc. — FDA 483 Findings
Inspectors Daniel J. RobertsThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Individual ADEs which were not reported to FDA in a post marketing 15-day alert have not been included in a periodic safety report.
Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.